What can organizations – both in research and in technology – do to help define that future?
CRO mergers affect the agility and speed of operations and may hamper efforts to bring in new technologies but at the same time can add significant value to both the pharmaceutical industry and the patients who depend on the life-saving medicines it produces.
Best practices to ensure a successful sponsor-CRO collaboration
Life science industry peers can share knowledge and strategies as they make adjustments and strive to establish new best practices and navigate necessary system changes.
Avoid additional work and expense by mastering dual IRB and IBC review.
CROs & Sponsors: Have we overcome the limitations of early site payment solutions? Learn how a Site Payment Advisory Group helped improve site payment technology for all stakeholders.
Provide EDC users the benefits that are essential to successful clinical data management.
Study helps further understand the current processes related to reconciling payments at research sites, the level of satisfaction at research sites around receivables, as well as the impact that reconciling payments from sponsors / CROs has on the site’s ability to conduct a clinical trial.
How to offer superior value-add by enhancing a site’s clinical trial experience for improved outcomes, strengthening the relationship and positioning sites for future trial success.
FDA guidance document specifically emphasizes the importance of analyzing study participant payments in order to reduce the likelihood of coercion.
|
|
|
|
|
|
|
|
|